Have a clinical diagnosis of Stage IA, Stage IB, or Stage IIA mycosis fungoides (cutaneous T-cell lymphoma), without clinically significant lymphadenopathy (≥1.5 centimeters).
Have 3 to 5 active, treatment-accessible mycosis fungoides lesions; ulcerated lesions and lesions to the face, neck, inguinal folds and intergluteal cleft are not considered suitable for administration of study drug.
Have baseline organ function (without transfusion support within 30 days of Cycle 1 Day 1) as defined by the protocol.
You may not be if
Have Stage IIB to IVB mycosis fungoides or Sezary syndrome.
Have histopathologically confirmed lymph node involvement.
Received systemic treatment with a phosphoinositide 3-kinases inhibitor in the 60 days prior to starting study drug.
Received topical steroids or other topical treatment (for example, nitrogen mustard) on mycosis fungoides lesions in the 2 weeks prior to starting study drug. Participants who receive such agents may become eligible for the study after a 14-day washout period.
Received systemic steroids, immunosuppressants (for example, cyclosporine, prednisone), psoralen ultraviolet A radiation therapy, narrow-band ultraviolet B light therapy, carmustine or other systemic therapies for mycosis fungoides in the 3 weeks prior to starting study drug.
Received electron beam irradiation within the 3 months prior to starting study drug.
